ADMA Company Profile and Key Details

Q: Who are the executives of ADMA?

Mr. Marc S. GelbergSenior Director & Corporation ControllerMr. Drew PantelloVice President of Marketing & Corporation Devel.Dr. Jerrold B. Grossman D.P.S., Ph.D.Co-Founder & Vice ChairmanMr. Brian Lenz CPA, CPAExecutive Vice President, Chief Financial Officer & GM of ADMA BioCentersDr. Gene A. Wetzstein BCOP, Pharm.D.Executive Director & Head of Scientific EngagementMr. Michael LeastVice President of Sales & Commercial OperationsMs. Cyndi TolmanSenior Vice President of Plasma ServicesMr. Adam S. GrossmanCo-Founder, Pres, Chief Executive Officer & DirectorMr. Brian Lenz C.P.A., CPAExecutive Vice President, Chief Financial Officer & GM of ADMA BioCentersMs. Cindy PetersenSenior Director of HRMr. Michael GoldsteinSenior Director & Gen. CounselMr. Skyler BloomSenior Director of Bus. Devel. & Corporation StrategyMs. Kaitlin KestenbergSenior Vice President of Compliance & Project OperationsMr. Neal C. FitzpatrickVice President of Sales

NASDAQ : ADMA

ADMA Biologics

$10.31

-0.21-2.00%

At Close 4:00 PM

60.59

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

ADMA Biologics, Inc. (ADMA) stock declined over -2.00%, trading at $10.31 on NASDAQ, down from the previous close of $10.52. The stock opened at $10.45, fluctuating between $10.13 and $10.66 in the recent session.

Stock Snapshot

10.52

Prev. Close

2.4B

Market Cap

10.125

Day Low

17.18

P/E Ratio

0.6

EPS (TTM)

0.02

Cash Flow per Share

10.45

Open

232.32M

Number of Shares

10.655

Day High

98%

Free Float in %

0.6

Book Value

7.87M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
May 04, 2026	10.45	10.65	10.13	10.31	7.8M
Apr 30, 2026	10.65	10.85	10.19	10.25	7.3M
Apr 29, 2026	10.81	10.88	10.41	10.60	4.26M
Apr 28, 2026	10.91	11.05	10.68	10.90	3.74M
Apr 27, 2026	11.25	11.33	10.92	10.93	5.55M
Apr 23, 2026	10.85	11.29	10.85	11.08	6.03M
Apr 22, 2026	10.83	11.16	10.63	10.95	4.97M
Apr 21, 2026	11.12	11.33	10.64	10.78	5.23M
Apr 20, 2026	10.85	11.05	10.68	10.88	4.88M
Apr 17, 2026	11.00	11.20	10.77	11.01	20.22M
Apr 16, 2026	10.65	10.93	10.42	10.74	4.57M
Apr 14, 2026	10.36	10.76	10.32	10.49	5.71M
Apr 13, 2026	9.74	10.56	9.68	10.38	5.44M
Apr 10, 2026	9.88	10.02	9.66	9.70	3.86M
Apr 09, 2026	9.66	10.15	9.60	9.94	4.8M
Apr 08, 2026	9.59	9.91	9.32	9.83	5.53M
Apr 07, 2026	9.22	9.45	9.09	9.26	3.39M
Apr 06, 2026	9.22	9.53	9.21	9.28	3.83M
Apr 02, 2026	8.90	9.26	8.80	9.19	6.12M
Apr 01, 2026	9.04	9.60	8.99	9.11	7.78M

Contact Details

Ramsey, NJ 07446

United States

https://www.admabiologics.com 201 478 5552

About Company

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Stock Peers

ARGX

27.59+3.52%

argenx SE$811.09 REGN

7.79+1.11%

Regeneron Pharmaceuticals, Inc.$709.21 UTHR

10.82+1.90%

United Therapeutics Corporation$581.22 MDGL

4.94002+0.96%

Madrigal Pharmaceuticals, Inc.$518.66 VRTX

5.93+1.40%

Vertex Pharmaceuticals Incorporated$429.85 PRAX

13.41+4.14%

Praxis Precision Medicines, Inc.$337.61 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ALNY

1.815+0.61%

Alnylam Pharmaceuticals, Inc.$297.93 KRYS

20.91+7.86%

Krystal Biotech, Inc.$286.95 SGEN

-0.16-0.07%

Seagen Inc.$228.74

Company Overview

ADMA Biologics, Inc. (NASDAQ:ADMA) closed at $10.31 USD, losing -$0.21 (-2.00%) from the previous close of $10.52. The stock is currently mid-range between its 52-week high and low $7.21 and $23.98. With a market capitalization of about $2.40 billion, ADMA Biologics, Inc. is classified as a mid-cap and shows market-like volatility (beta ~0.82). Key stats such as the average daily volume over the past year has been around 6.23 million shares, in line with its 52-week average. Headquartered in Ramsey, NJ, ADMA Biologics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Adam S. Grossman, the company employs approximately 685 people and listed since October 17, 2013. ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.

Technical Performance

Short-term trend indicators are mixed aligned (SMA20 -6.82%, SMA50 -13.02%, SMA200 -12.97%). The stock’s 14-day RSI is 35.45 (weak momentum), while the ATR of 0.79 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -40.86% below its high and over 12.44% above its low. Average 10-day trading volume of 5.73 million shares is in line with the 3-month average of 5.73 million, indicating normal recent market interest.

Valuation Metrics

ADMA Biologics, Inc. trades at a P/E ratio of 16.72, slightly below the S&P 500 average, with a price-to-sales ratio of 4.7 and a price-to-book ratio of 5.15 trading at moderately above to book value. The P/FCF stands at 86.19, also below market averages.

Dividend & Fair Value

ADMA Biologics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.04. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Wall Street analysts project EPS growth of 33.57% annually over the next five years. The latest quarter delivered EPS of $0.20. The next quarter is forecast at $0.19. Next year's EPS is expected at $690.91. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $24.00 to $21.00. The high target offers 132.78% upside. The low target suggests 103.69% downside. The mean target is $22.50. This offers 118.23% upside. ADMA Biologics, Inc. earnings surprise history is a mixed track record. The quarter that ended February 25, 2026, missed forecasts by 8.11%. The prior quarter beat by 0.06%. Over the last six quarters, Apple has recorded several small beats. These include 15.38% in November 07, 2024.

Shareholding & Insider Activity

ADMA Biologics, Inc. has 232.32 million shares outstanding. The public float is 233.02 million shares, elevated short interest at 10.16% of float. This equals 19.31 million shares. The short ratio is 2.02 days. Institutional investors hold 97.52% of the float. Insiders own 2.57%. PERCEPTIVE ADVISORS LLC holds 13.26 million shares, Biotest Divestiture Trust has 4.30 million shares and Grossman Adam S has 2.11 million shares. Over the past six months, insider transactions show net selling. They sold 34.10 thousand shares across 5 transactions.

Financial & Profitability Overview

Over the trailing twelve months, ADMA Biologics generated $258.21M in revenue, or $1.15 per share. Gross margin was 34.16%, operating margin 8.38%, and net profit margin -10.94%. Returns are negative, with ROA at -8.58% and ROE at -20.89%.
On valuation metrics, ADMA Biologics trades at a P/E of 16.72, P/S of 4.70 and P/B of 5.15. The current ratio is 6.71 and quick ratio is 3.74. Operationally, the company’s inventory turnover is 1.05 and cash conversion cycle is 422.17 days. Debt-to-equity is 0.17, supported by a cash flow-to-debt ratio of 0.63.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, ADMA Biologics posted revenue of $258.21M, down slightly from $154.08M in the prior quarter. Gross profit was $88.22M (margin 34.16%). Operating income was $21.63M (margin 8.4%). Net income was- $28.24M (EPS - $0.13).
The company ended the quarter with $51.35M in cash and short-term investments, a total debt of $141.42M, and net debt of $90.07M. Total assets were $329.18M, with equity of $135.21M. Financials further reflected stability, with operating cash flow of $8.80M, free cash flow of $3.82M, and capital expenditures of - $4.98M.

Price Forecast & Outlook

Our AI price prediction model suggests that ADMA Biologics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -13.77%, with price expected at $8.89 by May 18, 2026, within a range of $6.69 to $11.14 3-Month Outlook: Projected fall of -52.67%, reaching $4.88 by July 31, 2026, with a range of $4.23 to $5.44. 1-Year Outlook: Projected gain of 89.62%, with price at $19.55 by May 04, 2027, within a range of $19.13 to $20.13.

Key Takeaways

ADMA Biologics, Inc. (NASDAQ:ADMA) shares are flat -3.56% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows ADMA Biologics, Inc. trading at a premium to the broader market with a P/E of 16.72. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $12.14, suggesting 17.75% upside. Our AI forecast model points to short-term weakness (-13.77% over two weeks), a medium-term fall (-52.67% over three months), and a longer-term gain (89.62% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current ADMA Biologics, Inc. (ADMA) stock price?

ADMA Biologics, Inc. (NASDAQ: ADMA) stock price is $10.31 in the last trading session. During the trading session, ADMA stock reached the peak price of $10.66 while $10.13 was the lowest point it dropped to. The percentage change in ADMA stock occurred in the recent session was -2% while the dollar amount for the price change in ADMA stock was - $0.21.

ADMA's industry and sector of operation?

The NASDAQ listed ADMA is part of Biotechnology industry that operates in the broader Healthcare sector. ADMA Biologics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of ADMA?

Mr. Marc S. Gelberg
Senior Director & Corporation Controller
Mr. Drew Pantello
Vice President of Marketing & Corporation Devel.
Dr. Jerrold B. Grossman D.P.S., Ph.D.
Co-Founder & Vice Chairman
Mr. Brian Lenz CPA, CPA
Executive Vice President, Chief Financial Officer & GM of ADMA BioCenters
Dr. Gene A. Wetzstein BCOP, Pharm.D.
Executive Director & Head of Scientific Engagement
Mr. Michael Least
Vice President of Sales & Commercial Operations
Ms. Cyndi Tolman
Senior Vice President of Plasma Services
Mr. Adam S. Grossman
Co-Founder, Pres, Chief Executive Officer & Director
Mr. Brian Lenz C.P.A., CPA
Executive Vice President, Chief Financial Officer & GM of ADMA BioCenters
Ms. Cindy Petersen
Senior Director of HR
Mr. Michael Goldstein
Senior Director & Gen. Counsel
Mr. Skyler Bloom
Senior Director of Bus. Devel. & Corporation Strategy
Ms. Kaitlin Kestenberg
Senior Vice President of Compliance & Project Operations
Mr. Neal C. Fitzpatrick
Vice President of Sales

How ADMA did perform over past 52-week?

ADMA's closing price is 43% higher than its 52-week low of $7.21 where as its distance from 52-week high of $23.98 is -57.34%.

How many employees does ADMA have?

Number of ADMA employees currently stands at 685.

Link for ADMA official website?

Official Website of ADMA is: https://www.admabiologics.com

How do I contact ADMA?

ADMA could be contacted at phone 201 478 5552 and can also be accessed through its website. ADMA operates from 465 State Route 17, Ramsey, NJ 07446, United States.

How many shares of ADMA are traded daily?

ADMA stock volume for the day was 7.87M shares. The average number of ADMA shares traded daily for last 3 months was 6.23M.

What is the market cap of ADMA currently?

The market value of ADMA currently stands at $2.40B with its latest stock price at $10.31 and 232.32M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	685
Beta	0.82
Sales or Revenue	$258.21M
5Y Sales Change%	2.067%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

ADMA Company Profile and Key Details

ADMA Biologics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Earnings & Analyst Outlook

Shareholding & Insider Activity

Company Overview

Dividend & Fair Value

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Valuation Metrics